These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8083332)

  • 1. [Experimental study of the effects of hormonal therapy and intralesional injections of interleukin 2, activated macrophages on mouse prostate cancer models].
    Ikeda K
    Nihon Ika Daigaku Zasshi; 1994 Aug; 61(4):278-85. PubMed ID: 8083332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of murine transitional cell carcinoma with intralesional interleukin 2 and murine interferon gamma.
    Sosnowski JT; DeHaven JI; Riggs DR; Lamm DL
    J Urol; 1991 Oct; 146(4):1164-7. PubMed ID: 1910098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A study to increase the therapeutic effects of adoptive immunotherapy in vivo. Influence on the generation of lymphokine activated killer (LAK) cells and therapeutic effects of LAK cells with anti-tumor drug (cyclophosphamide)].
    Yoshimori K
    Nihon Ika Daigaku Zasshi; 1992 Oct; 59(5):418-27. PubMed ID: 1430114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
    Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
    Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor target-derived soluble factor synergizes with IFN-gamma and IL-2 to activate macrophages for tumor necrosis factor and nitric oxide production to mediate cytotoxicity of the same target.
    Jiang H; Stewart CA; Fast DJ; Leu RW
    J Immunol; 1992 Sep; 149(6):2137-46. PubMed ID: 1517576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice.
    Zhang F; Lu W; Dong Z
    Clin Cancer Res; 2002 Sep; 8(9):2942-51. PubMed ID: 12231540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
    Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
    Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
    Silagi S; Dutkowski R; Schaefer A
    Int J Cancer; 1988 Feb; 41(2):315-22. PubMed ID: 3123404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
    Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
    Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in liver tumors: II. Intratumoral injection with activated tumor-infiltrating lymphocytes, intrasplenic administration of recombinant interleukin-2 and interferon alpha causes tumor regression and lysis.
    Liu DL; Håkansson CH; Seifert J
    Cancer Lett; 1994 Sep; 85(1):39-46. PubMed ID: 7923100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
    Tjota A; Zhang YQ; Piedmonte MR; Lee CL
    J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and in vitro activation of alveolar macrophages by recombinant interferon-gamma.
    Black CM; Catterall JR; Remington JS
    J Immunol; 1987 Jan; 138(2):491-5. PubMed ID: 3098846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth.
    Kawakita M; Rao GS; Ritchey JK; Ornstein DK; Hudson MA; Tartaglia J; Paoletti E; Humphrey PA; Harmon TJ; Ratliff TL
    J Natl Cancer Inst; 1997 Mar; 89(6):428-36. PubMed ID: 9091644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inability of recombinant interferon-gamma to activate the antibacterial activity of mouse peritoneal macrophages against Listeria monocytogenes and Salmonella typhimurium.
    van Dissel JT; Stikkelbroeck JJ; Michel BC; van den Barselaar MT; Leijh PC; van Furth R
    J Immunol; 1987 Sep; 139(5):1673-8. PubMed ID: 2957433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex.
    Bermudez LE; Young LS
    J Immunol; 1988 May; 140(9):3006-13. PubMed ID: 2834450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral rIL2-based immunotherapy in B16 melanoma.
    Yeung RS; Vollmer C; Taylor DD; Palazzo J; Weese JL
    J Surg Res; 1992 Aug; 53(2):203-10. PubMed ID: 1405610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation.
    Oyama N; Ponde DE; Dence C; Kim J; Tai YC; Welch MJ
    J Nucl Med; 2004 Mar; 45(3):519-25. PubMed ID: 15001697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
    Iigo M; Nishikata K; Nakajima Y; Moriyama M
    Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.